Novo Nordisk AS (NVO) — Q2 FY26 Earnings Call Live coverage with Benzinga. Q2 FY26 Results EPS: $0.96 (est. $0.81) — inline Revenue: $12.21B (est. $11.35B) — inline Reported: 2026-08-04 Recent Quarters Q1 FY26 (2026-05-06): EPS $1.04 vs est $0.87 · Rev $15.17B vs est $11.13B Q4 FY25 (2026-02-04): EPS $1.00 vs est $0.89 · Rev $12.34B vs est $12.08B Q3 FY25 (2025-11-05): EPS $1.03 vs est $0.77 · Rev $11.74B vs est $11.88B Q2 FY25 (2025-08-06): EPS $0.91 vs est $0.93 · Rev $11.68B vs est $11.79B About Novo Nordisk AS With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. https://www.novonordisk.com · Bagsvaerd, DNK · 69,500 employees Follow Benzinga X: https://x.com/Benzinga Facebook: https://www.facebook.com/Benzinga/ Instagram: https://www.instagram.com/benzinga/ ⚠️ Disclaimer: Investing in financial markets carries risk, and there are no guaranteed returns. All information is for educational purposes only and should not be taken as financial advice. Always do your own research and speak with a qualified financial advisor before making investment decisions. Only invest what you can afford to lose. Past performance does not guarantee future outcomes. #earnings #NVO #stocks #benzinga